Focus on Paclitaxel and 5-Fluorouracil
Focus on Paclitaxel and 5-Fluorouracil
Mon Sep 23, 2013  5:00 - 6:30 PM 
Milano

Objectives:

At the end of the session, the participants will be able to:

  • Understand threshold models as a surrogate for paclitaxel-related hematological and non-hematological toxicity
  • Understand steady-state plasma concentrations as a surrogate for 5FU-related toxicity and clinical activity
  • Know logistical issues and practical issues that have to be dealt when performing TDM of 5FU

Description:

This Session will discuss therapeutic drug monitoring (TDM) of paclitaxel and 5FU in patients with solid tumors. Threshold models have been used retrospectively to describe the relationship between 3-weekly paclitaxel pharmacokinetics and hematological as well as non-hematological toxicity. Only recently, the clinical value of TDM of 3-weekly paclitaxel is undergoing prospective testing. With 5FU, several non-randomized and one randomized study suggest a clinical benefit from TDM. Still, some logistical and practical issues have to be considered when implementing TDM of continous-intravenous 5FU.